Results 191 to 200 of about 378,823 (394)

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando   +17 more
wiley   +1 more source

Validation study of a new chemiluminescent singleplex IgE assay in a set of Italian allergic rhinitis patients [PDF]

open access: hybrid, 2020
Ekaterina Potapova   +10 more
openalex   +1 more source

Distinct Nasal Microbiome Profiles and Prediction Model for Allergic Rhinitis, Nonallergic Rhinitis, and Healthy Children

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
The alpha and beta diversity of the nasal microbiome differed among children with allergic rhinitis (AR), nonallergic rhinitis (NAR), and healthy controls (HCs). Compared to HC, AR had more Escherichia‐Shigella, Negativicoccus, and Campylobacter, while NAR had more Dolosigranulum and fewer Enterobacteriaceae.
Kantima Kanchanapoomi   +6 more
wiley   +1 more source

Morphological Sinus Features and Chronic Rhinosinusitis Risk: A Radiomics Study

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objectives Anatomical factors of the sinuses significantly impact the progression of chronic rhinosinusitis (CRS). This study aims to investigate the correlation between morphological sinus features and the risk of CRS onset to provide evidence‐based support for clinical management.
Song Luo   +4 more
wiley   +1 more source

Clinical Characteristics and Risk Factors for Cutaneous Manifestations Associated With Nemolizumab in Atopic Dermatitis: A Multicenter Retrospective Study in Japan

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Nemolizumab, an anti‐interleukin‐31 receptor A monoclonal antibody, has been approved in Japan for treating atopic dermatitis (AD)‐associated pruritus. While it is effective for itch control, nemolizumab‐associated cutaneous adverse events have been increasingly recognized, yet their clinical features remain poorly characterized. In this study,
Wataru Sasaki   +24 more
wiley   +1 more source

Determination of Interleukin 31 (IL-31) serum levels according to severity of allergic rhinitis

open access: diamond, 2015
Noor Suryani Mohd Ashari   +4 more
openalex   +2 more sources

Home - About - Disclaimer - Privacy